Navigation Links
David Bagley Joins Histogen as President
Date:1/14/2009

Regenerative Medicine Company Poised for Product and Business Development Successes in the New Year

San Diego, CA (PRWEB) January 14, 2009-- Histogen, Inc., a regenerative medicine company developing solutions based on the products of newborn fibroblasts, announced today that David Bagley has joined the Company as President. Histogen welcomes Bagley following a year of rapid growth, with product launches, clinical evaluations and a new facility move on the horizon.

"With the launch of Histogen's first product, the creation of an aesthetics division, and talented new members joining the team in 2008, we've laid the groundwork for exciting progress in the coming year," said Dr. Gail Naughton, Histogen CEO and Chairman of the Board. "I am pleased to welcome David Bagley to Histogen, and believe his business experience and background in the field of tissue engineering will be a great asset to Histogen as we move forward."

David Bagley brings more than 20 years of cell biology and tissue engineering industry experience to Histogen. He has been a contributor to operational, scientific and engineering advancements in the development of several technologies including cell culture, tissue engineered and cell-based products for the treatment of multiple critical diseases, wound care and aesthetic product applications.

Most recently, Bagley served as Vice President and General Manager for Allergan Medical, Inc. with a focus on operations, technology, global distribution, quality and business disciplines. Prior to this, he held positions with Smith + Nephew/Advanced Tissue Sciences for over 12 years, where his latest position was Vice President of Technology and Logistics.

Previously, Bagley worked for Sigma Chemical Company where he was involved in the development and launch of several tissue culture product lines. Early in his career, he worked for HyClone Laboratories and Clonetics, both manufacturers and providers of cell culture products for various markets. Bagley has a B.S. degree in biology from Utah State University and a Master's degree in business from the American Graduate School of International Management in Arizona.

"Tissue engineering and cell-based products show a great deal of promise in the treatment of critical diseases and improving the lives of many people, however the development and launching of these complex products can be a challenge," said Bagley. "I am excited to join Histogen as President, and look forward to progressing these products and technologies to market."

About Histogen
Histogen, launched in 2007, seeks to redefine regenerative medicine by developing a series of high value products without the use of embryonic stem cells or animal products. Through Histogen's proprietary bioreactors that mimic the embryonic environment, newborn fibroblasts are encouraged to naturally produce the vital proteins and growth factors from which the company has developed its rich product portfolio. Histogen has two product families - ExceltrixTM, Histogen's human Extracellular Matrix (ECM) and ReGenicaTM, Histogen's proprietary liquid formula. The Company recently launched its first product - BioNuesisTM Human Stem Cell Culturing Kits - and announced the creation of its cosmeceutical venture - Histogen Aesthetics. For more information, please visit www.histogeninc.com.

###

Read the full story at http://www.prweb.com/releases/Histogen/Bagley/prweb1861514.htm


'/>"/>
Source: PRWeb
Copyright©2009 Vocus, Inc.
All rights reserved

Related biology technology :

1. BrainCells Inc. Appoints David E. Thompson to Its Board of Directors
2. Prominent Urologist Dr. David B. Samadi Presents Breakthrough Robotic Surgery Techniques on OR Live Webcast
3. PercSys Names David Auth and Howard Palefsky to Its Board of Directors
4. David H. Murdock Research Institute Taps Waters for Laboratory Technology
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Lumiphore Partners with Biophor Diagnostics, Inc. to Develop Tests for Drugs of Abuse; Appoints Ibis Biosciences Founder David J. Ecker to Board
7. David Hsia, Ph.D. Joins Kinex Pharmaceuticals Board of Directors
8. Trusted LASIK Surgeons Welcomes Leading LASIK Eye Surgery Expert, Inventor David Huang, M.D., Los Angeles, to Its Unique Lasik Directory Service
9. Encorium Appoints David Ginsberg President and Chief Executive Officer, Announces Changes to the Board of Directors
10. [video] David Brown, President and CEO of LifeVantage Corporation, Discusses Record Page Views on WallSt.nets 3-Minute Press Show
11. Omeros Appoints David A. Mann to its Board of Directors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/19/2016)... ... May 19, 2016 , ... KCAS Bioanalytical and Biomarker Services, ... Director, Large Molecule & Biomarker Bioanalysis. , Dr. Siddiqui has more than 15 ... for preclinical and clinical safety programs. “We’ve seen significant demand for, and we ...
(Date:5/18/2016)... 2016 The Biotech industry continues to ... that there are no opportunities ahead. Today, ActiveWallSt.com has on ... THLD ), Seattle Genetics Inc. (NASDAQ: SGEN ... Corp. (NASDAQ: OPHT ). Sign up now to ... http://www.activewallst.com/ Threshold Pharmaceuticals Inc.,s shares gained ...
(Date:5/17/2016)... -- Haselmeier announces the launch by Merck ... EMA, the European Medicines Agency. Originally launched in 2011 ... new pen version includes enhancements to further improve the ... patients during use. Its enhanced design has ... with a larger display window that improves the readability ...
(Date:5/17/2016)... BASEL, Switzerland , May 17, 2016 /PRNewswire/ ... sciences company located in Basel, Switzerland ... an investigational oral inhibitor of P38 mitogen-activated protein ... ) , Strekin will build the ... Pamapimod in indications in which MAP Kinases play ...
Breaking Biology Technology:
(Date:5/9/2016)... UAE, May 9, 2016 Elevay ... comes to expanding freedom for high net worth professionals ... in today,s globally connected world, there is still no ... could ever duplicate sealing your deal with a firm ... passports by taking advantage of citizenship via investment programs ...
(Date:4/28/2016)... 28, 2016 First quarter 2016:   ... compared with the first quarter of 2015 The gross ... M (loss: 18.8) and the operating margin was 40% (-13) ... Cash flow from operations was SEK 249.9 M (21.2) , ... is unchanged, SEK 7,000-8,500 M. The operating margin for ...
(Date:4/19/2016)... The new GEZE SecuLogic access ... "all-in-one" system solution for all door components. It can ... door interface with integration authorization management system, and thus ... minimal dimensions of the access control and the optimum ... offer considerable freedom of design with regard to the ...
Breaking Biology News(10 mins):